ES2543567T3 - Métodos de utilización de inhibidores de ALK - Google Patents
Métodos de utilización de inhibidores de ALK Download PDFInfo
- Publication number
- ES2543567T3 ES2543567T3 ES12703670.5T ES12703670T ES2543567T3 ES 2543567 T3 ES2543567 T3 ES 2543567T3 ES 12703670 T ES12703670 T ES 12703670T ES 2543567 T3 ES2543567 T3 ES 2543567T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- methods
- formula
- alk inhibitors
- alk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 abstract 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 abstract 1
- 229960005061 crizotinib Drugs 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- VOASCOSDVNWJEV-UHFFFAOYSA-N 5-chloro-2-n-(5-methyl-4-piperidin-2-yl-2-propan-2-yloxyphenyl)-4-n-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCCCN1 VOASCOSDVNWJEV-UHFFFAOYSA-N 0.000 description 1
- IGUPHIBNKHHSSE-UHFFFAOYSA-N 5-chloro-2-n-(5-methyl-4-piperidin-3-yl-2-propan-2-yloxyphenyl)-4-n-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCCNC1 IGUPHIBNKHHSSE-UHFFFAOYSA-N 0.000 description 1
- VOASCOSDVNWJEV-JOCHJYFZSA-N 5-chloro-2-n-[5-methyl-4-[(2r)-piperidin-2-yl]-2-propan-2-yloxyphenyl]-4-n-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1[C@H]1CCCCN1 VOASCOSDVNWJEV-JOCHJYFZSA-N 0.000 description 1
- VOASCOSDVNWJEV-QFIPXVFZSA-N 5-chloro-2-n-[5-methyl-4-[(2s)-piperidin-2-yl]-2-propan-2-yloxyphenyl]-4-n-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1[C@@H]1CCCCN1 VOASCOSDVNWJEV-QFIPXVFZSA-N 0.000 description 1
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438878P | 2011-02-02 | 2011-02-02 | |
| US201161438878P | 2011-02-02 | ||
| PCT/US2012/023669 WO2012106540A1 (en) | 2011-02-02 | 2012-02-02 | Methods of using alk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2543567T3 true ES2543567T3 (es) | 2015-08-20 |
Family
ID=45582065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12703670.5T Active ES2543567T3 (es) | 2011-02-02 | 2012-02-02 | Métodos de utilización de inhibidores de ALK |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8703787B2 (OSRAM) |
| EP (1) | EP2670401B1 (OSRAM) |
| JP (1) | JP5837095B2 (OSRAM) |
| KR (1) | KR101521861B1 (OSRAM) |
| CN (1) | CN103458881B (OSRAM) |
| AU (1) | AU2012212142B2 (OSRAM) |
| BR (1) | BR112013019643B1 (OSRAM) |
| CA (1) | CA2824092C (OSRAM) |
| CY (1) | CY1116662T1 (OSRAM) |
| DK (1) | DK2670401T3 (OSRAM) |
| EA (1) | EA023404B1 (OSRAM) |
| ES (1) | ES2543567T3 (OSRAM) |
| HR (1) | HRP20150946T1 (OSRAM) |
| HU (1) | HUE025395T2 (OSRAM) |
| ME (1) | ME02200B (OSRAM) |
| MX (1) | MX2013008791A (OSRAM) |
| PL (1) | PL2670401T3 (OSRAM) |
| PT (1) | PT2670401E (OSRAM) |
| RS (1) | RS54189B1 (OSRAM) |
| SI (1) | SI2670401T1 (OSRAM) |
| SM (1) | SMT201500300B (OSRAM) |
| WO (1) | WO2012106540A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102156398B1 (ko) | 2012-11-06 | 2020-09-15 | 상하이 포천 파마슈티컬 씨오 엘티디 | Ａｌｋ 키나아제 억제제 |
| IN2015DN04175A (OSRAM) * | 2012-11-07 | 2015-10-16 | Novartis Ag | |
| CN104109149B (zh) * | 2013-04-22 | 2018-09-28 | 苏州泽璟生物制药有限公司 | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 |
| ITMI20131124A1 (it) * | 2013-07-04 | 2015-01-05 | Univ Milano Bicocca | 2-acilamminotiazoli per il trattamento del cancro |
| WO2015003658A1 (en) * | 2013-07-11 | 2015-01-15 | Betta Pharmaceuticals Co., Ltd | Protein tyrosine kinase modulators and methods of use |
| JP6479812B2 (ja) * | 2013-08-28 | 2019-03-06 | ノバルティス アーゲー | 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ |
| CN104672214B (zh) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| MX2016008362A (es) * | 2013-12-23 | 2016-09-08 | Novartis Ag | Combinaciones farmaceuticas. |
| CN104876914B (zh) * | 2014-02-28 | 2017-04-19 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| KR101733733B1 (ko) * | 2014-06-17 | 2017-05-11 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| CN105524045B (zh) * | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
| CN106146525B (zh) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | 三并环类间变性淋巴瘤激酶抑制剂 |
| US10259816B2 (en) | 2015-04-24 | 2019-04-16 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof |
| CN106699743B (zh) | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
| CN106220608B (zh) * | 2016-07-25 | 2018-11-27 | 安润医药科技（苏州）有限公司 | 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途 |
| CN107698603B (zh) * | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
| CN109715620B (zh) * | 2016-08-29 | 2022-05-06 | 密歇根大学董事会 | 作为alk抑制剂的氨基嘧啶 |
| CN111484484B (zh) * | 2020-04-13 | 2021-11-23 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| JP4607879B2 (ja) * | 2003-08-15 | 2011-01-05 | ノバルティス アーゲー | 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| ES2444222T3 (es) | 2006-07-10 | 2014-02-24 | Goji Limited | Preparación de alimentos |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| RS53588B1 (sr) * | 2006-12-08 | 2015-02-27 | Irm Llc | Jedinjenja i kompozicije kao inhibitori protein kinaza |
| BRPI0720264B1 (pt) * | 2006-12-08 | 2022-03-03 | Novartis Ag | Compostos e composições como inibidores de proteína cinase |
| CA2720946C (en) * | 2008-04-07 | 2013-05-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
-
2012
- 2012-02-02 ME MEP-2015-127A patent/ME02200B/me unknown
- 2012-02-02 PT PT127036705T patent/PT2670401E/pt unknown
- 2012-02-02 ES ES12703670.5T patent/ES2543567T3/es active Active
- 2012-02-02 DK DK12703670.5T patent/DK2670401T3/en active
- 2012-02-02 HR HRP20150946TT patent/HRP20150946T1/hr unknown
- 2012-02-02 CA CA2824092A patent/CA2824092C/en active Active
- 2012-02-02 EP EP12703670.5A patent/EP2670401B1/en active Active
- 2012-02-02 CN CN201280007465.9A patent/CN103458881B/zh active Active
- 2012-02-02 BR BR112013019643-2A patent/BR112013019643B1/pt active IP Right Grant
- 2012-02-02 WO PCT/US2012/023669 patent/WO2012106540A1/en not_active Ceased
- 2012-02-02 AU AU2012212142A patent/AU2012212142B2/en active Active
- 2012-02-02 MX MX2013008791A patent/MX2013008791A/es unknown
- 2012-02-02 PL PL12703670T patent/PL2670401T3/pl unknown
- 2012-02-02 HU HUE12703670A patent/HUE025395T2/en unknown
- 2012-02-02 SI SI201230285T patent/SI2670401T1/sl unknown
- 2012-02-02 US US13/981,046 patent/US8703787B2/en active Active
- 2012-02-02 RS RS20150563A patent/RS54189B1/sr unknown
- 2012-02-02 KR KR1020137023001A patent/KR101521861B1/ko active Active
- 2012-02-02 EA EA201391114A patent/EA023404B1/ru not_active IP Right Cessation
- 2012-02-02 JP JP2013552637A patent/JP5837095B2/ja active Active
-
2015
- 2015-08-28 CY CY20151100758T patent/CY1116662T1/el unknown
- 2015-11-30 SM SM201500300T patent/SMT201500300B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE025395T2 (en) | 2016-02-29 |
| PT2670401E (pt) | 2015-10-12 |
| EA201391114A1 (ru) | 2013-12-30 |
| CN103458881B (zh) | 2015-08-12 |
| SMT201500300B (it) | 2016-01-08 |
| CA2824092C (en) | 2020-06-30 |
| MX2013008791A (es) | 2013-10-07 |
| DK2670401T3 (en) | 2015-09-07 |
| KR20130121174A (ko) | 2013-11-05 |
| WO2012106540A1 (en) | 2012-08-09 |
| EP2670401B1 (en) | 2015-06-10 |
| SI2670401T1 (sl) | 2015-10-30 |
| PL2670401T3 (pl) | 2015-11-30 |
| EP2670401A1 (en) | 2013-12-11 |
| BR112013019643B1 (pt) | 2022-04-19 |
| US20130296357A1 (en) | 2013-11-07 |
| EA023404B1 (ru) | 2016-05-31 |
| CY1116662T1 (el) | 2017-03-15 |
| AU2012212142A1 (en) | 2013-08-15 |
| KR101521861B1 (ko) | 2015-05-21 |
| US8703787B2 (en) | 2014-04-22 |
| CN103458881A (zh) | 2013-12-18 |
| HRP20150946T1 (hr) | 2015-10-09 |
| BR112013019643A2 (pt) | 2016-10-04 |
| JP2014504646A (ja) | 2014-02-24 |
| CA2824092A1 (en) | 2012-08-09 |
| JP5837095B2 (ja) | 2015-12-24 |
| ME02200B (me) | 2016-02-20 |
| RS54189B1 (sr) | 2015-12-31 |
| AU2012212142B2 (en) | 2015-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2543567T3 (es) | Métodos de utilización de inhibidores de ALK | |
| ES2524966T3 (es) | Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer | |
| AR073136A1 (es) | Compuestos de pirrol | |
| PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| PE20141380A1 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| AR106237A2 (es) | Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables | |
| AR063601A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| CY1118879T1 (el) | Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor | |
| PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
| AR088092A1 (es) | Procesos para preparar inhibidores de quinasas atr utiles para el tratamiento del cancer | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| ES2531274T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
| AR106744A2 (es) | Formas cristalinas de un compuesto de bifenilo | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| PE20170939A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| AR083578A1 (es) | INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA | |
| PE20141583A1 (es) | Nuevos derivados de piridina | |
| ES2723277T3 (es) | Una forma sólida de clorhidrato de (S)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| EA201491079A1 (ru) | Арил дигидропиридиноновые и пиперидиноновые ингибиторы mgat2 | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. |